Loading
Micromet developed BiTE antibodies, which link the body's T cells to cancer cells so the T cells can kill them. Amgen bought it in 2012 for blinatumomab, a BiTE antibody for acute lymphoblastic leukaemia.
Micromet was a Nasdaq-listed (MITI) biotechnology company founded in Germany, with research and development in Munich and headquarters in Rockville, Maryland, built on its BiTE (bispecific T cell engager) antibody platform. Amgen agreed on 26 January 2012 to acquire it for $11 a share in cash, valuing it at about $1.16 billion, for blinatumomab, then in Phase 2 for acute lymphoblastic leukaemia and also in development for non-Hodgkin lymphoma. Amgen completed its tender offer on 7 March 2012 with 88.34 per cent of shares tendered. Atlas Venture lists Micromet as making biologics for cancer, sold to Amgen in 2012.
Blinatumomab was the first T-cell engager (2014), and is now given to children and adults with leukaemia even when in remission, because it improves survival.
Shares Blinatumomab, Amgen, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares Blinatumomab, Amgen, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares Blinatumomab, Amgen, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares Amgen, Bispecific antibodies, T-cell engagers (bispecific).
Shares Amgen, Bispecific antibodies, T-cell engagers (bispecific).
Shares Amgen, Bispecific antibodies, T-cell engagers (bispecific).
Shares Amgen, Bispecific antibodies, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/